MLH1 and melanoma: Specifically, a major role of altered expression levels of DNMTs has been described in the development of resistance to temozolomide (TMZ) through the silencing of the DNA mismatch repair gene MLH1, while increased levels of DNMT1 have been associated with Vemurafenib-resistant tumors among stage IV melanoma patients [53,54,55].